TABLE 1.

Inhibitory and binding properties of the hits identified in the present study

Assay conditions are described under Materials and Methods. The results represent the average of triplicate measurements ± S.D.

Hit	Residual CYP46A1 Activitya	Kdb	Ki	Indication or Use
	%	μM
In silico prediction
Bicalutamide	35 ± 2.0	1.2 ± 0.05	NM	Antineoplastic
Dexmedetomidine	8.0 ± 0.3	0.02 ± 0.005	0.13 ± 0.01	Analgesic, sedative
Epinephrine	25 ± 2.0	NSP	NM	Adrenergic stimulant
Estradiol	32 ± 6.0	NSP	NM	Steroid hormone
FLV (E-isomer)	11 ± 0.2	0.7 ± 0.1	1.7 ± 0.3	Antidepressant
Isoproterenol	25 ± 2.0	NSP	NM	Bronchodilator
Mitomycin	41 ± 1.0	NSP	NM	Antineoplastic
Testosterone	49 ± 4.0	NSP	NM	Steroid hormone
Intuitive predictions
Albaconazole	35 ± 3.0	2.5 ± 0.1	NM	Antifungal
Ephedrine	49 ± 2.0	NSP	NM	Bronchodilator
Hexaconazole	46 ± 3.0	0.4 ± 0.02	NM	Antifungal
Posaconazole	13 ± 1.2	0.3 ± 0.03	NM	Antifungal
Ravuconazole	50 ± 3.0	0.6 ± 0.02	NM	Antifungal

NM, not measured; NSP, weak or no spectral response.

^a Activity in the screening enzyme assay.

^b Calculated on the basis of spectral binding.